PRPH: ProPhase Labs, Inc. Common Stock (DE) Company Profile & Statistics

About

ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE?, a zinc gluconate glycine product. COLD-EEZE? family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.

Info & Links

CEO

Ted Karkus

Headquarters

711 STEWART AVENUE, SUITE 200
GARDEN CITY, NY 11530, UNITED STATES

Auditor

Morison Cogen LLP

Share holders

162

Employees

113

ProPhase Labs, Inc. Common Stock (DE) Statistics

Valuation Measures

Market Capitalization²

12.72M

Enterprise Value

36.59M

Enterprise Value/EBITDA(ttm)

-1.39

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.10

Price to Book(mrq)

0.30

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

-30.93%

Operating Margin(ttm)

-217.64%

Profit Margin(ttm)

-220.15%

Return on Equity(ttm)

-62.92%

Return on Invested Capital(ttm)

-46.49%

Return on Assets(ttm)

-30.22%

Income Statement

Revenue(ttm)

12.75M

Revenue Per Share(ttm)

0.53

Gross Profit(ttm)

-4.13M

EBITDA(ttm)³

-26.41M

Net Income Available to Common(ttm)

-27.76M

Diluted EPS(ttm)

-1.26

Share Statistics

Beta (5Y Monthly)

-0.37

52-Week Change

-88.10%

S&P 500 52-Week Change

18.16%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

23.87M

Dividend Yield

0.00%

Float⁴

18.93M

% Held by Insiders

20.70%

% Held by Institutions

9.45%

Balance Sheet

Total Cash(mrq)

1.10M

Total Cash Per Share(mrq)

0.05

Total Debt(mrq)

24.96M

Total Debt/Equity(mrq)

65.47%

Current Ratio(mrq)

1.47%

Quick Ratio(mrq)

1.33%

Book Value Per Share(mrq)

2.00

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.73

Free Cash Flow(ytd)

-14.88M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

PRPH

ProPhase Labs, Inc. Common Stock (DE)

ProPhase Labs, Inc. Common Stock (DE) Profile